|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2019. CA Cancer J Clin. 69:7–34. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Herbst RS, Heymach JV and Lippman SM: Lung
cancer. N Engl J Med. 359:1367–1380. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Chansky K, Sculier JP, Crowley JJ, et al:
The International Association for the Study of Lung Cancer Staging
Project: prognostic factors and pathologic TNM stage in surgically
managed non-small cell lung cancer. J Thorac Oncol. 4:792–801.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ma B, Simala-Grant JL and Taylor DE:
Fucosylation in prokaryotes and eukaryotes. Glycobiology.
16:158R–184R. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Adamczyk B, Tharmalingam T and Rudd PM:
Glycans as cancer biomarkers. Biochim Biophys Acta. 1820:1347–1353.
2012. View Article : Google Scholar
|
|
6
|
Miyoshi E, Moriwaki K, Terao N, Tan CC,
Terao M, Nakagawa T, Matsumoto H, Shinzaki S and Kamada Y:
Fucosylation is a promising target for cancer diagnosis and
therapy. Biomolecules. 2:34–45. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Tuccillo FM, de Laurentiis A, Palmieri C,
Fiume G, Bonelli P, Borrelli A, Tassone P, Scala I, Buonaguro FM,
Quinto I, et al: Aberrant glycosylation as biomarker for cancer:
Focus on CD43. BioMed Res Int. 2014:7428312014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Miyoshi E, Moriwaki K and Nakagawa T:
Biological function of fucosylation in cancer biology. J Biochem.
143:725–729. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kim HJ, Kim SC, Ju W, Kim YH, Yin SY and
Kim HJ: Aberrant sialylation and fucosylation of intracellular
proteins in cervical tissue are critical markers of cervical
carcinogenesis. Oncol Rep. 31:1417–1422. 2014. View Article : Google Scholar
|
|
10
|
Zhu J, Wang Y, Yu Y, et al: Aberrant
fucosylation of glycosphin-golipids in human hepatocellular
carcinoma tissues. Liver Int. 34:147–160. 2014. View Article : Google Scholar
|
|
11
|
Munkley J, Mills IG and Elliott DJ: The
role of glycans in the development and progression of prostate
cancer. Nat Rev Urol. 13:324–333. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Sawa M, Hsu TL, Itoh T, Sugiyama M, Hanson
SR, Vogt PK and Wong CH: Glycoproteomic probes for fluorescent
imaging of fucosylated glycans in vivo. Proc Natl Acad Sci USA.
103:12371–12376. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Becker DJ and Lowe JB: Fucose:
Biosynthesis and biological function in mammals. Glycobiology.
13:41R–53R. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Oriol R, Mollicone R, Cailleau A,
Balanzino L and Breton C: Divergent evolution of fucosyltransferase
genes from vertebrates, invertebrates, and bacteria. Glycobiology.
9:323–334. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Tu Z, Lin YN and Lin CH: Development of
fucosyltransferase and fucosidase inhibitors. Chem Soc Rev.
42:4459–4475. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Merino P, Tejero T, Delso I,
Hurtado-Guerrero R, Gómez-SanJuan A and Sádaba D: Recent progress
on fucosyltransferase inhibitors. Mini Rev Med Chem. 12:1455–1464.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Mollicone R, Moore SE, Bovin N,
Garcia-Rosasco M, Candelier JJ, Martinez-Duncker I and Oriol R:
Activity, splice variants, conserved peptide motifs, and phylogeny
of two new alpha1,3-fucosyltransferase families (FUT10 and FUT11).
J Biol Chem. 284:4723–4738. 2009. View Article : Google Scholar
|
|
18
|
Guo Q, Guo B, Wang Y, Wu J, Jiang W, Zhao
S, Qiao S and Wu Y: Functional analysis of
α1,3/4-fucosyltransferase VI in human hepatocellular carcinoma
cells. Biochem Biophys Res Commun. 417:311–317. 2012. View Article : Google Scholar
|
|
19
|
Barthel SR, Wiese GK, Cho J, Opperman MJ,
Hays DL, Siddiqui J, Pienta KJ, Furie B and Dimitroff CJ: Alpha 1,3
fucosyltransferases are master regulators of prostate cancer cell
trafficking. Proc Natl Acad Sci USA. 106:19491–19496. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Muinelo-Romay L, Vázquez-Martín C,
Villar-Portela S, Cuevas E, Gil-Martín E and Fernández-Briera A:
Expression and enzyme activity of alpha(1,6)fucosyltransferase in
human colorectal cancer. Int J Cancer. 123:641–646. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Chen CY, Jan YH, Juan YH, Yang CJ, Huang
MS, Yu CJ, Yang PC, Hsiao M, Hsu TL and Wong CH: Fucosyltransferase
8 as a functional regulator of nonsmall cell lung cancer. Proc Natl
Acad Sci USA. 110:630–635. 2013. View Article : Google Scholar
|
|
22
|
Carvalho AS, Harduin-Lepers A, Magalhães
A, Machado E, Mendes N, Costa LT, Matthiesen R, Almeida R, Costa J
and Reis CA: Differential expression of
alpha-2,3-sialyltransferases and alpha-1,3/4-fucosyltransferases
regulates the levels of sialyl Lewis a and sialyl Lewis x in
gastrointestinal carcinoma cells. Int J Biochem Cell Biol.
42:80–89. 2010. View Article : Google Scholar
|
|
23
|
Li W, Zhang W, Luo J, Cao A, Zhang Y,
Huang D, Sheng W, Cai S and Li J: Alpha1,3 fucosyltransferase VII
plays a role in colorectal carcinoma metastases by promoting the
carbohy-dration of glycoprotein CD24. Oncol Rep. 23:1609–1617.
2010.PubMed/NCBI
|
|
24
|
Wang X, Chen J, Li QK, Peskoe SB, Zhang B,
Choi C, Platz EA and Zhang H: Overexpression of α (1,6)
fucosyltransferase associated with aggressive prostate cancer.
Glycobiology. 24:935–944. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Yang X, Liu S and Yan Q: Role of
fucosyltransferase IV in epithelial-mesenchymal transition in
breast cancer cells. Cell Death Dis. 4:e7352013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Honma R, Kinoshita I, Miyoshi E, Tomaru U,
Matsuno Y, Shimizu Y, Takeuchi S, Kobayashi Y, Kaga K, Taniguchi N,
et al: Expression of fucosyltransferase 8 is associated with an
unfavorable clinical outcome in non-small cell lung cancers.
Oncology. 88:298–308. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ma L, Dong P, Liu L, Gao Q, Duan M, Zhang
S, Chen S, Xue R and Wang X: Overexpression of protein
O-fucosyltransferase 1 accelerates hepatocellular carcinoma
progression via the Notch signaling pathway. Biochem Biophys Res
Commun. 473:503–510. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Okayama H, Kohno T, Ishii Y, Shimada Y,
Shiraishi K, Iwakawa R, Furuta K, Tsuta K, Shibata T, Yamamoto S,
et al: Identification of genes upregulated in ALK-positive and
EGFR/KRAS/ALK-negative lung adenocarcinomas. Cancer Res.
72:100–111. 2012. View Article : Google Scholar
|
|
29
|
Rousseaux S, Debernardi A, Jacquiau B,
Vitte AL, Vesin A, Nagy-Mignotte H, Moro-Sibilot D, Brichon PY,
Lantuejoul S, Hainaut P, et al: Ectopic activation of germline and
placental genes identifies aggressive metastasis-prone lung
cancers. Sci Transl Med. 5:186ra662013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Xie Y, Xiao G, Coombes KR, Behrens C,
Solis LM, Raso G, Girard L, Erickson HS, Roth J, Heymach JV, et al:
Robust gene expression signature from formalin-fixed
paraffin-embedded samples predicts prognosis of non-small-cell lung
cancer patients. Clin Cancer Res. 17:5705–5714. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Botling J, Edlund K, Lohr M, Hellwig B,
Holmberg L, Lambe M, Berglund A, Ekman S, Bergqvist M, Pontén F, et
al: Biomarker discovery in non-small cell lung cancer: Integrating
gene expression profiling, meta-analysis, and tissue microarray
validation. Clin Cancer Res. 19:194–204. 2013. View Article : Google Scholar
|
|
32
|
Der SD, Sykes J, Pintilie M, Zhu CQ,
Strumpf D, Liu N, Jurisica I, Shepherd FA and Tsao MS: Validation
of a histology-independent prognostic gene signature for
early-stage, non-small-cell lung cancer including stage IA
patients. J Thorac Oncol. 9:59–64. 2014. View Article : Google Scholar
|
|
33
|
Zhu Y, Qiu P and Ji Y: TCGA-assembler:
Open-source software for retrieving and processing TCGA data. Nat
Methods. 11:599–600. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Eijssen LM, Jaillard M, Adriaens ME, Gaj
S, de Groot PJ, Müller M and Evelo CT: User-friendly solutions for
microarray quality control and pre-processing on ArrayAnalysis.org.
Nucleic Acids Res. 41(W1): W71–6. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Lee S, Chun JN, Kim SH, So I and Jeon JH:
Icilin inhibits E2F1-mediated cell cycle regulatory programs in
prostate cancer. Biochem Biophys Res Commun. 441:1005–1010. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Lee S, Park YR, Kim SH, Park EJ, Kang MJ,
So I, Chun JN and Jeon JH: Geraniol suppresses prostate cancer
growth through down-regulation of E2F8. Cancer Med. 5:2899–2908.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Fabregat A, Korninger F, Viteri G,
Sidiropoulos K, Marin-Garcia P, Ping P, Wu G, Stein L, D'Eustachio
P and Hermjakob H: Reactome graph database: Efficient access to
complex pathway data. PLOS Comput Biol. 14:e10059682018. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Park EJ, Chun JN, Kim SH, Kim CY, Lee HJ,
Kim HK, Park JK, Lee SW, So I and Jeon JH: Schisandrin B suppresses
TGFβ1 signaling by inhibiting Smad2/3 and MAPK pathways. Biochem
Pharmacol. 83:378–384. 2012. View Article : Google Scholar
|
|
39
|
Chun JN, Kim SY, Park EJ, Kwon EJ, Bae DJ,
Kim IS, Kim HK, Park JK, Lee SW, Park HH, et al: Schisandrin B
suppresses TGFβ1-induced stress fiber formation by inhibiting
myosin light chain phosphorylation. J Ethnopharmacol. 152:364–371.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Kim JS, Kim JG, Moon MY, Jeon CY, Won HY,
Kim HJ, Jeon YJ, Seo JY, Kim JI, Kim J, et al: Transforming growth
factor-beta1 regulates macrophage migration via RhoA. Blood.
108:1821–1829. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Liu J, Hu G, Chen D, Gong AY, Soori GS,
Dobleman TJ and Chen XM: Suppression of SCARA5 by Snail1 is
essential for EMT-associated cell migration of A549 cells.
Oncogenesis. 2:e732013. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Hirakawa M, Takimoto R, Tamura F, Yoshida
M, Ono M, Murase K, Sato Y, Osuga T, Sato T, Iyama S, et al:
Fucosylated TGF-β receptors transduces a signal for
epithelial-mesenchymal transition in colorectal cancer cells. Br J
Cancer. 110:156–163. 2014. View Article : Google Scholar
|
|
43
|
Lin H, Wang D, Wu T, Dong C, Shen N, Sun
Y, Sun Y, Xie H, Wang N and Shan L: Blocking core fucosylation of
TGF-β1 receptors downregulates their functions and attenuates the
epithelial-mesenchymal transition of renal tubular cells. Am J
Physiol Renal Physiol. 300:F1017–F1025. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Larsen JE, Nathan V, Osborne JK, Farrow
RK, Deb D, Sullivan JP, Dospoy PD, Augustyn A, Hight SK, Sato M, et
al: ZEB1 drives epithelial-to-mesenchymal transition in lung
cancer. J Clin Invest. 126:3219–3235. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Li J, Guillebon AD, Hsu JW, Barthel SR,
Dimitroff CJ, Lee YF and King MR: Human fucosyltransferase 6
enables prostate cancer metastasis to bone. Br J Cancer.
109:3014–3022. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Padua D and Massagué J: Roles of TGFbeta
in metastasis. Cell Res. 19:89–102. 2009. View Article : Google Scholar
|
|
47
|
Drabsch Y and ten Dijke P: TGF-β
signalling and its role in cancer progression and metastasis.
Cancer Metastasis Rev. 31:553–568. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Fukushima K, Satoh T, Baba S and Yamashita
K: alpha1,2-Fucosylated and beta-N-acetylgalactosaminylated
prostate-specific antigen as an efficient marker of prostatic
cancer. Glycobiology. 20:452–460. 2010. View Article : Google Scholar
|
